- Home
- XPRO vs RCUS Comparison
XPRO vs RCUS Comparison
Compare XPRO & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPRO
- RCUS
- Stock Information
- Founded
- XPRO 1938
- RCUS 2015
- Country
- XPRO United States
- RCUS United States
- Employees
- XPRO N/A
- RCUS N/A
- Industry
- XPRO Oilfield Services/Equipment
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- XPRO Energy
- RCUS Health Care
- Exchange
- XPRO Nasdaq
- RCUS Nasdaq
- Market Cap
- XPRO 1.4B
- RCUS 1.2B
- IPO Year
- XPRO 2013
- RCUS 2018
- Fundamental
- Price
- XPRO $12.35
- RCUS $12.44
- Analyst Decision
- XPRO Buy
- RCUS Buy
- Analyst Count
- XPRO 4
- RCUS 8
- Target Price
- XPRO $12.50
- RCUS $20.71
- AVG Volume (30 Days)
- XPRO 1.0M
- RCUS 727.5K
- Earning Date
- XPRO 10-23-2025
- RCUS 11-05-2025
- Dividend Yield
- XPRO N/A
- RCUS N/A
- EPS Growth
- XPRO N/A
- RCUS N/A
- EPS
- XPRO 0.61
- RCUS N/A
- Revenue
- XPRO $1,673,283,000.00
- RCUS $262,000,000.00
- Revenue This Year
- XPRO N/A
- RCUS N/A
- Revenue Next Year
- XPRO $3.65
- RCUS N/A
- P/E Ratio
- XPRO $20.40
- RCUS N/A
- Revenue Growth
- XPRO 2.67
- RCUS 6.07
- 52 Week Low
- XPRO $6.70
- RCUS $6.50
- 52 Week High
- XPRO $18.56
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- XPRO 58.61
- RCUS 70.00
- Support Level
- XPRO $11.98
- RCUS $11.30
- Resistance Level
- XPRO $12.58
- RCUS $12.05
- Average True Range (ATR)
- XPRO 0.44
- RCUS 0.58
- MACD
- XPRO -0.10
- RCUS 0.05
- Stochastic Oscillator
- XPRO 57.33
- RCUS 97.66
About XPRO Expro Group Holdings N.V.
Expro Group Holdings NV offers products and services that span the well life cycle, including well construction, well flow management, well intervention and integrity, and subsea well access. It maintains operations around the world and specializes in offshore production solutions. It also provides production optimization for both onshore and offshore applications. The company has four operating segments: North and Latin America (NLA); Europe and Sub-Saharan Africa (ESSA); Middle East and North Africa (MENA), and Asia-Pacific (APAC). The majority of its revenue is derived from North and Latin America (NLA) segment.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.